Current studies into retatruptide peptide demonstrate notable outlook for treating obesity and non-insulin dependent disease. The molecule, a dual activator of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, looks to offer enhanced weight reduction and glucose control co